Glomerular hyperfiltration and renal disease progression in type 2 diabetes

Diabetes Care

Volumn 35, Issue 10, 2012, Pages 2061-2068

  Ruggenenti, Piero ^a,b   Porrini, Esteban L ^a   Gaspari, Flavio ^a   Motterlini, Nicola ^a   Cannata, Antonio ^a   Carrara, Fabiola ^a   Cella, Claudia ^a   Ferrari, Silvia ^a   Stucchi, Nadia ^a   Parvanova, Aneliya ^a   Iliev, Ilian ^a   Dodesini, Alessandro Roberto ^b   Trevisan, Roberto ^b   Bossi, Antonio ^c   Zaletel, Jelka ^d   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c TREVIGLIO HOSPITAL   (Italy)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

DELAPRIL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; IOHEXOL; ORAL ANTIDIABETIC AGENT; PLACEBO; TRANDOLAPRIL;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC DIET; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; ENZYME INHIBITION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE DISPOSAL RATE; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; LONGITUDINAL STUDY; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MICROALBUMINURIA; NEPHELOMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA CLEARANCE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; URINALYSIS;

AGED; ALBUMINURIA; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY GLOMERULUS; MALE; MIDDLE AGED;

EID: 84866656037     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2189     Document Type: Article

References (37)

1. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930
2. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009;52:691-697
3. Yip JW, Jones SL, Wiseman MJ, Hill C, Viberti G. Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study. Diabetes 1996;45:1729-1733
4. Silveiro SP, Friedman R, de Azevedo MJ, Canani LH, Gross JL. Five-year prospective study of glomerular filtration rate and albumin excretion rate in normofiltering and hyperfiltering normoalbuminuric NIDDM patients. Diabetes Care 1996;19:171-174
5. Fontseré N, Salinas I, Bonal J, et al. Are prediction equations for glomerular filtration rate useful for the long-term monitoring of type 2 diabetic patients? Nephrol Dial Transplant 2006;21:2152-2158
6. Andersen S, Bröchner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003;26:3296-3302
7. Moriya T, Tsuchiya A, Okizaki S, Hayashi A, Tanaka K, Shichiri M. Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo- and micro-albuminuric type 2 diabetes. Kidney Int 2012;81:486-493
8. Chaiken RL, Eckert-Norton M, Bard M, et al. Hyperfiltration in African-American patients with type 2 diabetes. Cross-sectional and longitudinal data. Diabetes Care 1998;21:2129-2134
9. Nelson RG, Bennett PH, Beck GJ, et al.; Diabetic Renal Disease Study Group. Development and progression of renal disease in Pima Indianswith non-insulin-dependent diabetes mellitus. N Engl J Med 1996;335:1636-1642
10. Ruggenenti P, Fassi A, Ilieva AP, et al.; BENEDICT-B Study Investigators. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens 2011;29:207-216
11. Ruggenenti P, Lauria G, Iliev IP, et al.; DEMAND Study Investigators. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial. Hypertension 2011;58:776-783
12. Gaspari F, Perico N, Ruggenenti P, et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995;6:257-263
13. Gaspari F, Perico N, Matalone M, et al. Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol 1998;9:310-313
14. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252-1256
15. Gaspari F, Ferrari S, Stucchi N, et al.; MY.S.S. Study Investigators. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 2004;4:1826-1835
16. Parvanova AI, Trevisan R, Iliev IP, et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 2006;55:1456-1462
17. Beck GJ, Berg RL, Coggins CH, et al.; The Modification of Diet in Renal Disease Study Group. Design and statistical issues of the Modification of Diet in Renal Disease Trial. Control Clin Trials 1991;12:566-586
18. Gassman JJ, Greene T, Wright JT Jr, et al. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 2003;14(Suppl. 2):S154-S165
19. BENEDICT Group. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. Control Clin Trials 2003;24:442-461
20. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving HH. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995;47:1726-1731
21. Barnett AG, van der Pols JC, Dobson AJ. Regression to themean: what it is and how to deal with it. Int J Epidemiol 2005;34:215-220
22. Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG.Meta-analysis of continuous outcome data from individual patients. Stat Med 2001;20:2219-2241
23. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997;16:2349-2380
24. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-285
25. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976;31:155-163
26. Chudleigh RA, Dunseath G, Evans W, et al. How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes? Diabetes Care 2007;30:300-305
27. Bash LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2008;168:2440-2447
28. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-3277
29. Pavkov ME, Knowler WC, Lemley KV, Mason CC, Myers BD, Nelson RG. Early renal function decline in type 2 diabetes. Clin J Am Soc Nephrol 2012;7:78-84
30. Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int 2006;70:1214-1222
31. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878
32. Ruggenenti P, Fassi A, Ilieva AP, et al.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951
33. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-1179
34. Thomaseth K, Pacini G, Morelli P, Tonolo G, Nosadini R. Importance of glycemic control on the course of glomerular filtration rate in type 2 diabetes with hypertension and microalbuminuria under tight blood pressure control. Nutr Metab Cardiovasc Dis 2008;18:632-638
35. Wright JT Jr, Bakris G, Greene T, et al.; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results fromthe AASK trial. JAMA 2002;288:2421-2431
36. Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev 2006;22:98-107
37. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia 2010;53:2093-2104